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Abstract
Background: Tocotrienols (T3) and tocopherols (T), both members of the natural vitamin E family have unique
biological functions in humans. T3 are detected in circulating human plasma and lipoproteins, although at
concentrations significantly lower than a-tocopherol (a-T). T3, especially a-T3 is known to be neuropotective at
nanomolar concentrations and this study evaluated the postprandial fate of T3 and a-T in plasma and lipoproteins.
Methods: Ten healthy volunteers (5 males and 5 females) were administered a single dose of vitamin E [526 mg
palm tocotrienol-rich fraction (TRF) or 537 mg a-T] after 7-d pre-conditioning on a T3-free diet. Blood was sampled
at baseline (fasted) and 2, 4, 5, 6, 8, and 24 h after supplementation. Concentrations of T and T3 isomers in plasma,
triacylglycerol-rich particles (TRP), LDL, and HDL were measured at each postprandial interval.
Results: After TRF supplementation, plasma a-T3 and g-T3 peaked at 5 h (a-T3: 4.74 ± 1.69 μM; g-T3: 2.73 ± 1.27
μM). δ-T3 peaked earlier at 4 h (0.53 ± 0.25 μM). In contrast, a-T peaked at 6 h (30.13 ± 2.91 μM) and 8 h (37.80 ±
3.59 μM) following supplementation with TRF and a-T, respectively. a-T was the major vitamin E isomer detected
in plasma, TRP, LDL, and HDL even after supplementation with TRF (composed of 70% T3). No T3 were detected
during fasted states. T3 are detected postprandially only after TRF supplementation and concentrations were
significantly lower than a-T.
Conclusions: Bio-discrimination between vitamin E isomers in humans reduces the rate of T3 absorption and
affects their incorporation into lipoproteins. Although low absorption of T3 into circulation may impact some of
their physiological functions in humans, T3 have biological functions well below concentration noted in this study.
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Background
Vitamin E is the generic name for a group of 8 plant-
derived, lipid soluble substances ("tocols”) including four
tocopherol (T) and four tocotrienol (T3) derivatives. T3
are similar to T in molecular structure, except that they
have an isoprenoid tail with three unsaturation points
instead of a saturated phytyl chain. Vitamin E is a recog-
nized antioxidant and thought beneficial for human
health. There have been several indications that T3 may
result in superior therapeutic properties compared to T
[1-8].
The absorption and biokinetics of T3 in humans are
however not fully understood. Inter alia,t h ea b o v e
issues related to the absorption and biokinetics have
been linked to several findings relating the physiological
outcomes of T3 [9-12]. In comparison to a-T, the meta-
bolic pathways relevant to T3 have hardly been eluci-
dated and optimized. Several human studies have
investigated the absorption of T3 into circulating plasma
[9-11,13-21] and lipoproteins [2,19,20]. The detection of
T3 in plasma and lipoprotein fractions has proven diffi-
cult, possibly due to its low occurrence. In comparison
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Rapid disappearance of these T3 has raised questions
about their potential as potent lipid-soluble antioxidant.
This is most probably one of the reasons why T3 are
given a low score for their biological vitamin E activity
compared to a-T [22].
T as well as T3 are transported within lipoprotein par-
ticles while circulating in the blood, but their distribu-
tion in lipoproteins has been documented only
occasionally. Most studies investigating absorption of T3
in the human circulatory system focused on the plasma
content of T3. From these limited human studies
[2,19,20], distribution of T3 in lipoproteins was signifi-
cantly lower than that of a-T. Following postprandial
intervention, T3 transport in lipoproteins appears to fol-
low complex biochemically mediated pathways within
the lipoprotein cascade [19]. The mechanism of T3
transport in human lipoproteins has not been conclu-
sively investigated and discussed. Although laboratory
evidence has been very promising [5,8], T3 supplemen-
tation in humans has produced inconsistent results
[6,7]. In addition, most studies investigating the
response of T3 supplements, investigated only total
plasma concentration of T3 [9-13,16,17] and rarely in
various lipoprotein fractions [19,20].
Response of plasma and lipoproteins to T3 may be
determined by the dose of T3 supplementation. This
additionally could influence the fasting T3 level in blood
[14]. Since supplementation with high dose of T3 has
demonstrated that T3 were detected in plasma, TRP,
LDL, and HDL following 8-h of postprandial challenge
[19], it is intriguing to investigate whether lower dose of
T3 supplementation would also resulted a similar obser-
vation. Since a-T is the most bio-active form of vitamin
E [22], it is crucial to refer to a-T when comparing the
biological activity of other isomers of vitamin E includ-
ing T3. With this in mind, we investigated the metabolic
fate of T3 as well as a-T in plasma and lipoprotein frac-
tions in normolipemic humans through the current
postprandial study.
Methods
Subjects
10 volunteers (5 males and 5 females) who were
employees of the Malaysian Palm Oil Board (MPOB)
were recruited for the study. Each volunteer was briefed
on the objectives, design and protocol of the study
before signing a consent form. The study was approved
by the institutional ethics committee. All volunteers
were normolipemic, nonsmokers, and did not show any
clinical symptoms associated with lipid-related cardio-
vascular disease. Through the administration of a ques-
tionnaire and dietary interview, we established that none
of the volunteers consumed any vitamin or herbal
supplements nor were they taking any prescribed medi-
cation. Female volunteers were not pregnant, lactating,
or taking contraceptives at the time of enrollment. The
study was completed with the following baseline charac-
teristics of the 10 volunteers: (mean ± SD): age, 23.8 ±
5.53 y; body mass index, 20.4 ± 1.83 kg/m
2; plasma total
cholesterol (TC), 4.08 ± 0.92 mmol/L; and plasma total
triacylglycerol (TAG), 1.05 ± 0.34 mmol/L.
Study design
The study was designed to elucidate the absorption and
metabolic fate of palm T3 administered to humans in a
postprandial model system, and compared to that of a-
T at a similar dose. The dose selected was approxi-
mately 500 mg of vitamin E or 50% of the Tolerable
Upper Limit Intake (UL) in humans [22]. The study was
conducted in accordance to procedures published pre-
viously [19]. Volunteers were conditioned on a standar-
dized fat-controlled diet (comprising breakfast, lunch
and afternoon high tea) during a run-in period lasting 7
days for each rotation of the postprandial trial. Using a
cross-over design, volunteers were subjected to two
rotations whereby a-T and palm T3 rich-fraction (TRF)
supplements were administered separately. One week
wash-out period was allowed between each rotation.
Meals were cooked with corn oil as the dietary fat
source, and the same menu was repeated for each rota-
tion. Daily food samples were duplicated and analysed
for composition of fat and vitamin E. Content of fat and
total vitamin E in the standardized fat- controlled diet
was 48.0 ± 12.2 g/d and 14.9 ± 8.2 mg/d (4.7 ± 2.7 mg
a-T/d, 9.6 ± 5.2 mg g-T/d, and 0.6 ± 0.3 mg δ-T/d),
respectively.
Postprandial event
Volunteers fasted overnight (≥ 10 h) and reported to the
laboratory on the next morning. After their body weight
was recorded, 12 mL blood was drawn for a fasting,
baseline sample (0 h). The volunteers then consumed
the standardized test breakfast cooked with corn oil,
which included a weighed portion of fried rice, fried
potatoes, a slice of papaya, and tea. The test breakfast
contained 30.5 ± 8.2 g fat and 10.7 ± 1.7 mg total vita-
min E (3.2 ± 0.5 mg a-T, 7.1 ± 1.2 mg g-T, and 0.5 ±
0.07 mg δ-T). The volunteers were then challenged with
the vitamin E preparations: palm T3-rich fraction (TRF)
or a-T. For the TRF treatment, 4 capsules of TRF
(obtained in-house from the Agro Product Unit, MPOB)
were used to provide a total of 526 mg vitamin E (a-T,
167 mg; a-T3, 157 mg; b-T3, 15.2 mg; g-T3, 141.8 mg;
δ-T3, 45.2 mg). For a-T treatment, 2 capsules of RRR-
a-T (Natopherol
®, Abbot Laboratories, Australia) were
used to provide 537 mg vitamin E solely as a-T. This
entire exercise was completed within 20 min of the first
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taken postprandially at 2, 4, 5, 6 and 8 h after the meal
and vitamin E supplement were consumed. During this
postprandial challenge, volunteers abstained from con-
suming any food and were only allowed to consume
mineral water. They also refrained from any strenuous
activity within these intervals. Following the end of the
8-h postprandial blood sampling, the volunteers were
provided a full cooked meal with fat component con-
tributed solely by corn oil. Late in the evening, they also
consumed supper in their homes. On the next day after
an overnight fast, a fasted blood sample was again
drawn from each volunteer to complete the 24-h time
point.
Blood sampling and handling
Following blood collection into collection tubes contain-
ing EDTA (BD Vacutainer, Franklin Lakes, NJ), plasma
was isolated by centrifugation at 3000 × g for 20 min at
4°C. A fresh, 3 mL of recovered plasma was refrigerated
overnight at 4°C and subsequently used for preparation
of lipoprotein fractions; triacylglycerol-rich particles
(TRPs), LDL, and HDL. These lipoproteins were isolated
from plasma by sequential ultracentrifugation using a
50.4 Ti rotor (Beckman Instruments Inc, Palo Alto, CA),
as described previously [19,23]. The remaining plasma
samples were aliquoted and snap-frozen in liquid nitro-
gen and stored at -80°C until analysed.
Biochemical determinations
Plasma total cholesterol and triacylglycerol
Plasma lipids were analysed by enzymatic procedures
using a Roche-Hitachi 902 Clinical Autoanalyzer
(Roche-Hitachi, Japan) with reagents, calibrators, and
controls supplied by Roche Diagnostics GmbH, IN.
Vitamin E analysis in plasma and lipoprotein fractions
Plasma and lipoprotein fractions (TRP, LDL, HDL) were
extracted for vitamin E and analysed by HPLC as
described previously [19,24]. The system used was an
Agilent 1100 Series (Agilent Technologies Inc, Wald-
brohn, Germany). Two normal-phase 5-μm silica col-
u m n s( 4 . 6×2 5 0m m ;A g i l e n tZ o r b a xR x - S I L ,A g i l e n t
Technologies Inc, Palo Alto, CA) were fitted in series to
enhance the separation of all vitamin E isomers, with a
mobile phase consisting of hexane-isopropanol (flow
rate of 2 mL/min, pressure of 133 bar, run time of 25
min). Identification of the vitamin E isomers was done
using a fluorescence detector (Agilent 1100 Series, Agi-
lent Technologies), with excitation at 295 nm and emis-
sion at 330 nm, as described previously [19].
Statistical analysis
Postprandial responses were compared with the corre-
sponding baseline value (0 h) and their trend was
analysed by using repeated-measures analysis of var-
iance (ANOVA). Changes were calculated as the differ-
ence between responses at each postprandial interval
and baseline. Postprandial effects between treatments
on plasma profiles were analysed for their time × treat-
ment interaction by using two-factor repeated-mea-
sures ANOVA, whereas postprandial effects on
lipoprotein profiles were analysed for their time ×
treatment × group (lipoproteins) interactions by using
three-factor repeated-measures multiple analysis of
variance (MANOVA). Area under the curve (AUC),
which was defined as the total postprandial vitamin E
response for the 24-h period, was also determined with
the area normalized to the baseline concentration. Wil-
coxon’s signed-ranks test was performed to detect any
significant difference between variables of interest.
Results were presented as the mean ± SEM. Statistical
analyses were performed by using SPSS for WIN-
DOWS (version 11.0; SPSS Inc, Chigaco, IL), and sig-
nificance was set at P <0 . 0 5 .
Results
Postprandial lipid responses
Following both a-T and TRF treatments, no significant
changes were observed in plasma total cholesterol and
triacylglycerol concentrations (Table 1). No significant
changes in all lipid responses were observed between
treatments.
Postprandial plasma tocopherols responses
a-T was the predominant vitamin E isomer detected in
plasma throughout the entire postprandial intervals fol-
lowing both treatments. Plasma a-T concentrations
increased significantly starting from 4 h, before peaking
Table 1 Plasma total cholesterol and triacylglycerol
concentrations (mmol/L) following a-tocopherol and
tocotrienol-rich fraction (TRF) treatments (Mean values ±
SEM, n = 10).
Total cholesterol
(mmol/L)
Triacylglycerol
(mmol/L)
a-T TRF a-T TRF
0 h* 4.29 ± 0.19 4.45 ± 0.23 0.96 ± 0.04 1.05 ± 0.08
2 h 4.28 ± 0.23 4.34 ± 0.35 1.22 ± 0.09 1.30 ± 0.13
4 h 4.15 ± 0.24 4.33 ± 0.27 1.41 ± 0.15 1.37 ± 0.14
5 h 4.24 ± 0.26 4.33 ± 0.29 1.37 ± 0.14 1.29 ± 0.13
6 h 4.39 ± 0.23 4.54 ± 0.37 1.23 ± 0.07 1.31 ± 0.16
8 h 4.37 ± 0.25 4.58 ± 0.37 0.95 ± 0.06 1.02 ± 0.13
24 h 4.49 ± 0.23 4.35 ± 0.28 0.90 ± 0.05 0.91 ± 0.08
AUC 24 h 105.11 ± 5.53 106.78 ± 6.78 24.47 ± 1.37 25.35 ± 2.25
a-T, alpha-tocopherol; TRF, tocotrienol-rich fraction; AUC, area under the curve
(arbitrary units).
* No significant differences between the treatments at baseline (0 h) were
found for either total cholesterol or triacylglycerol (Wilcoxon’s signed-ranks
test).
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after supplementation with a-T and TRF, respectively
(Table 2). A similar pattern was reflected for plasma g-
T, which increased significantly from 4 h, peaked at 5
h (1.64 ± 0.15 μM) after a-T treatment, and 6 h (2.15
±0 . 4 1μM) after TRF treatment. There was no signifi-
cant time × treatment interaction of a-T and g-T con-
centrations between both treatments. However, plasma
total a-T concentrations throughout the postprandial
period (24 h) were significantly higher after the a-T
treatment compared to that of TRF treatment (mea-
sured as the AUC).
Postprandial plasma tocotrienols responses
Unlike during a-T treatment, supplementation with
TRF resulted in the incorpo r a t i o no fT 3i n t op l a s m a
and changes in the vitamin E composition. Following
TRF treatment, a-T3, g-T3 and δ-T3 were detected in
postprandial plasma (Figure 1), along with a-T and g-T.
However, concentration of a- T 3( 1 . 4 6±0 . 5 2t o4 . 7 4±
1.69 μM), g-T3 (0.90 ± 0.42 to 2.73 ± 1.27 μM) and δ-
T3 (0.14 ± 0.10 to 0.53 ± 0.25 μM) was significantly
lower compared to that of a-T (22.95 ± 1.26 to 30.13 ±
2.91 μM), even when volunteers were supplemented
with the tocotrienol-rich TRF. T3 were not detected in
fasting plasma samples (0 h) or 24 h after supplementa-
tion with TRF. All T3 isomers increased postprandially
starting from 2 h and thereafter peaked at 5 h (a-T3,
4.74 ± 1.69 μM; g-T3, 2.73 ± 1.27 μM) before declining
from 6 h onwards. δ-T3 was however peaked earlier at 4
h (0.53 ± 0.25 μM).
a-T3 was the major T3 isomer detected throughout
the whole postprandial period.
Distribution of tocopherols in lipoprotein fractions
The distribution of a-T and g-T in TRP, LDL, and HDL
was expressed as percentage of plasma total vitamin E
(Table 3). Concentration of a-T in all lipoprotein frac-
tions was significantly higher than g-T during both
treatments. However, only g-T in LDL and HDL
increased significantly from its baseline (0 h) values. Fol-
lowing TRF treatment, g-T in LDL increased signifi-
cantly from 4 h to 8 h, whereas after a-T treatment,
LDL g-T increased significantly only at 8 h. In HDL,
only g-T increased significantly from its baseline value
(from 4 h to 8 h) after supplementation with TRF. No
significant increment in postprandial a-T and g-T in
TRP were observed. In TRP, between 17.39 ± 1.72% to
33.34 ± 3.34%, and 17.96 ± 4.60% to 26.93 ± 3.53% of
total circulating plasma vitamin E was detected as a-T
during a-T and TRF treatments, respectively. a-T was
significantly higher in TRP (from 2 h to 6 h) following
a-T treatment versus the TRF treatment.
Distribution of tocotrienols in lipoprotein fractions
In general, all T3 isomers (a-T3, g-T3, δ-T3) except b-
T3 were detected in all lipoprotein fractions (TRP, LDL,
and HDL) following the TRF treatment although their
concentration were significantly lower than a-T. Among
the T3 isomers detected in TRP, LDL, and HDL, a-T3
was the major T3 isomer, followed by g-T3 and δ-T3. In
TRP, between 1.63 ± 0.57% to 4.65 ± 1.56% of total cir-
culating plasma vitamin E was a-T3 (Figure 2). Starting
at 2 h until 6 h, concentration of a-T3 was higher in
TRP, compared to LDL and HDL. TRP a-T3 peaked at
5 h and declined thereafter. In LDL and HDL, although
a-T3 peaked at 6 h, the TRP concentrations of this
Table 2 Plasma tocopherols (T) concentrations after
supplementation with the a-tocopherol or tocotrienol-
rich fraction (TRF) treatments (Mean values ± SEM, n =
10).
a-T TRF
a-T g-T a-T g-T
μM
0 h* 23.38 ± 1.03 0.36 ±
0.12
22.95 ± 1.26 0.35 ±
0.15
2 h 26.31 ± 1.81 0.63 ±
0.15
22.98 ± 1.20 0.57 ±
0.18
Change
† 2.90 ± 1.63 0.29 ±
0.14
0.05 ± 0.65 0.22 ±
0.17
4 h 32.65 ± 2.49
‡ 1.42 ±
0.12
‡
26.45 ± 1.89
‡ 1.70 ±
0.28
‡
Change 9.26 ± 1.00 1.06 ±
0.17
3.51 ± 1.23 1.34 ±
0.34
5 h 36.38 ± 3.17
‡ 1.64 ±
0.15
‡
28.15 ± 2.61
‡ 1.96 ±
0.40
‡
Change 12.98 ± 2.79 1.27 ±
0.22
5.20 ± 1.93 1.61 ±
0.46
6 h 37.4 ± 3.51
‡ 1.57 ±
0.17
‡
30.13 ± 2.91
‡ 2.15 ±
0.41
‡
Change 14.00 ± 3.25 1.22 ±
0.19
7.17 ± 2.18 1.80 ±
0.48
8 h 37.8 ± 3.59
‡ 1.48 ±
0.27
‡
29.79 ± 2.30
‡ 1.76 ±
0.22
‡
Change 14.39 ± 3.32 1.13 ±
0.29
6.85 ± 1.39 1.42 ±
0.29
24 h 32.92 ± 3.58 0.35 ±
0.16
26.79 ± 1.81 0.20 ±
0.11
Change 9.52 ± 3.41 -0.02 ±
0.17
3.83 ± 1.07 -0.14 ±
0.19
AUC 24 h 353.52 ±
30.40
§
9.92 ±
1.68
286.16 ±
19.85
§
11.10 ±
1.47
T, tocopherols; TRF, tocotrienol-rich fraction; AUC, area under the curve
(arbitrary unit); a-T, alpha-tocopherol; g-T, g-tocopherol.
* No significant differences in plasma a-T and g-T concentrations at baseline
(0 h) were found between the treatments.
† Changes were calculated as the difference between values at each
postprandial interval and baseline (0 h).
‡ Significant increment from baseline (0 h) value, P < 0.05 (Wilcoxon’s signed-
ranks test).
§ Significant difference of AUC for a-T between the treatments, P < 0.05
(Wilcoxon’s signed-ranks test).
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in LDL and HDL was between 0.97 ± 0.32% to 2.96 ±
0.85% and 1.62 ± 0.48% to 3.13 ± 0.68% of total circulat-
ing plasma vitamin E, respectively.
Starting from 2 h onwards, postprandial g-T3 concen-
tration in TRP and HDL increased gradually (Figure 3).
g-T3 concentration were similar in TRP and HDL, ran-
ging between 0.42 ± 0.22% to 2.05 ± 1.04% and 1.09 ±
0.51% to 1.98 ± 0.49% of total circulating plasma vita-
min E, respectively. g-T3 in HDL peaked at 4 h whereas
in TRP, g-T3 peaked an hour later at 5 h, before steadily
declining thereafter. Throughout the first 6-h postpran-
dial period, concentration of g-T3 was lower in LDL
compared to TRP and HDL. Between 0.61 ± 0.28% to
1.49 ± 0.35% of total circulating plasma vitamin E was
detected as g-T3 in LDL. After 8 h, concentration of g-
T3 was highest in HDL, intermediate in LDL, and low-
est in TRP.
Following the 8-h postprandial period, among the
lipoprotein fractions, HDL recorded the highest content
of δ-T3 (Figure 4). Concentration of δ-T3 in the HDL
was between 0.65 ± 0.28% and 0.47 ± 0.32% of total cir-
culating plasma vitamin E. Starting from 2 h, HDL δ-T3
increased gradually and peaked at 4 h before plateauing.
In LDL, δ-T3 increased steadily starting from 2 h,
peaked at 5 h and declined thereafter. Up to 0.20 ±
0.11% of total circulating plasma vitamin E was detected
as δ-T3 in LDL. Unlike LDL and HDL, δ-T3 in TRP
was only detected starting from 2 h until 6 h postpran-
dially. No δ-T3 was detected in TRP at 8 h. Concentra-
tion of δ-T3 in TRP was between 0.17 ± 0.12% to 0.27
± 0.18% of total circulating plasma vitamin E.
Discussion
Following both vitamin E treatments in the current
study, a-T was the major vitamin E detected in circulat-
ing plasma and lipoproteins. All vitamin E isomers from
dietary sources (including supplements) are absorbed
and delivered to the liver, although only a-T is preferen-
tially recognized by the a-tocopherol transfer protein
(a-TTP) for incorporation into circulating plasma [25].
Other T (g-T, δ-T) and T3 isomers (a-T3, g-T3, δ-T3)
are not preferentially utilized and are mostly excreted
from circulation [26]. This is the main reason why a-T
is the only vitamin E isomer that is currently used as
the standard to estimate human vitamin E requirements
[22]. However it is increasingly acknowledged that T3
and T serve different biological functions and bench
marking only a-T to estimate human vitamin E require-
ments may no longer be the most accurate measure
[3,5,8].
In the current study, supplementation with a-T or
TRF resulted in significantly increased plasma a-T con-
centration compared to the baseline value. Furthermore,
plasma total circulating a-T for the 24 h postprandial
duration (described as AUC) was significantly higher
Figure 1 Mean (± SEM) plasma tocotrienols (T3) concentrations in healthy volunteers (n = 10) after supplementation with the
tocotrienol-rich fraction (TRF). a-T3, a-tocotrienols (○); g-T3, g-tocotrienols (●) and δ-T3, δ-tocotrienols (Δ) were detected in plasma starting
from 2 h until 8 h. No T3 were detected at 0 h and 24 h. Inset: AUC, area under the curve, 0-8 h (arbitrary units) is presented as means ± SEM
(n = 10) for a-T3, g-T3 and δ-T3.
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Page 5 of 11Table 3 Distribution of tocopherols (T) in plasma lipoprotein fractions during supplementation with the a-tocopherol and tocotrienol-rich fraction (TRF)
treatments (mean values ± SEM, n = 10)*
a-T g-T
TRP LDL HDL TRP LDL HDL
a-T TRF a-T TRF a-T TRF a-T TRF a-T TRF a-T TRF
% %
0 h 18.21 ± 2.31 21.2 ± 4.79 39.53 ± 2.53 41.25 ± 3.67 40.73 ± 2.57 36.20 ± 2.84 0.08 ± 0.08 0.33 ± 0.21 0.46 ± 0.19 0.47 ± 0.21 1.00 ± 0.41 0.55 ± 0.24
2 h 29.85 ± 3.57 25.13 ± 4.02 33.48 ± 2.56 33.53 ± 3.80 34.34 ± 2.50 30.87 ± 2.87 0.79 ± 0.22 0.97 ± 0.41 0.51 ± 0.15 0.58 ± 0.23 1.02 ± 0.27 0.76 ± 0.23
Change
† 11.65 ± 2.44
§ 3.93 ± 1.24
§ -6.05 ± 1.66 -7.72 ± 2.58 -6.38 ± 1.71 -5.34 ± 1.10 0.72 ± 0.22 0.64 ± 0.31 0.05 ± 0.17 0.11 ± 0.27 0.01 ± 0.25 0.22 ± 0.29
4 h 33.34 ± 3.34 26.93 ± 3.53 30.74 ± 2.33 26.38 ± 2.78 31.78 ± 2.50 26.18 ± 2.89 2.02 ± 0.31 2.27 ± 0.54 0.80 ± 0.13 1.06 ± 0.18
‡ 1.32 ± 0.19 1.52 ± 0.22
‡
Change 15.14 ± 2.83
§ 5.73 ± 1.66
§ -8.79 ± 2.22 -14.48 ± 2.49 -8.95 ± 1.20 -10.02 ± 2.11 1.94 ± 0.34 1.95 ± 0.51 0.35 ± 0.21 0.59 ± 0.23 0.32 ± 0.34 0.97 ± 0.30
5 h 31.55 ± 3.29 26.40 ± 3.92 31.89 ± 2.13 25.97 ± 3.00 32.01 ± 2.34 26.12 ± 3.11 2.06 ± 0.39 2.37 ± 0.54 0.97 ± 0.08 1.19 ± 0.10
‡ 1.38 ± 0.20 1.61 ± 0.27
‡
Change 13.34 ± 2.77
§ 5.20 ± 1.72
§ -7.64 ± 1.58 -15.29 ± 3.12 -8.72 ± 1.75 -10.09 ± 2.01 1.99 ± 0.42 2.04 ± 0.49 0.51 ± 0.25 0.72 ± 0.20 0.38 ± 0.38 1.06 ± 0.35
6 h 27.76 ± 2.14 24.10 ± 4.29 36.27 ± 1.97 29.45 ± 3.47 31.58 ± 2.27 25.50 ± 2.52 1.81 ± 0.40 2.30 ± 0.59 1.04 ± 0.09 1.39 ± 0.16
‡ 1.40 ± 0.25 1.70 ± 0.22
‡
Change 9.55 ± 2.07
§ 2.90 ± 1.78
§ -3.26 ± 1.65 -11.80 ± 2.64 -9.15 ± 1.48 -10.71 ± 2.37 1.73 ± 0.43 1.97 ± 0.54 0.58 ± 0.28 0.92 ± 0.23 0.40 ± 0.37 1.15 ± 0.28
8 h 17.93 ± 2.24 17.96 ± 4.60 40.41 ± 1.83 35.74 ± 3.46 37.54 ± 1.99 31.26 ± 2.82 1.07 ± 0.35 1.36 ± 0.44 1.28 ± 0.20
‡ 1.62 ± 0.13
‡ 1.64 ± 0.39 1.97 ± 0.30
‡
Change -0.28 ± 2.15 -3.24 ± 1.85 0.88 ± 1.64 -5.52 ± 1.34 -3.18 ± 1.73 -4.95 ± 2.23 1.00 ± 0.37 1.04 ± 0.33 0.83 ± 0.34 1.14 ± 0.28 0.64 ± 0.36 1.43 ± 0.41
24 h 17.39 ± 1.72 19.94 ± 4.46 40.71 ± 2.38 38.82 ± 3.60 40.59 ± 2.11 40.42 ± 3.12 0.12 ± 0.09 0.21 ± 0.21 0.33 ± 0.19 0.18 ± 0.12 0.87 ± 0.45 0.43 ± 0.22
Change -0.82 ± 2.35 -1.26 ± 2.11 1.17 ± 2.27 -2.43 ± 1.92 -0.15 ± 1.16 4.22 ± 1.35 0.05 ± 0.10 -0.12 ± 0.88 -0.13 ± 0.22 -0.18 ± 0.23 -0.13 ± 0.49 0.01 ± 0.34
AUC 501.58 ± 42.79 495.54 ± 101.10 928.26 ± 40.04 805.20 ± 73.76 899.04 ± 45.72 806.29 ± 62.67 20.07 ± 5.26 25.37 ± 7.97 19.38 ± 2.92 22.53 ± 2.10 30.25 ± 7.60 29.72 ± 5.02
TRF, tocotrienol-rich fraction; TRP, triacylglycerol rich particles; AUC, area under the curve (arbitrary unit); a-T, a-tocopherol; g-T, g-tocopherol.
* Significant time × treatment × group (lipoproteins) interaction of a-T were found (3-factor repeated-measures MANOVA).
† Changes were calculated as the difference between values at each postprandial interval and baseline (0 h).
‡ Significant increment from baseline (0 h) value, P < 0.05 (Wilcoxon’s signed-ranks test).
§ Significant difference of a-T content in TRP between a-tocopherol and TRF treatments, P < 0.05 (Wilcoxon’s signed-ranks test)
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1after a-T treatment. This observation was however
anticipated, due to the higher content of a-T adminis-
tered (537 mg of a- T )f r o mt h ea-T treatment com-
pared to that of TRF (only 167 mg a-T).
In most human clinical and bioavailability studies of
vitamin E, only the plasma and lipoprotein concentra-
tions of a-T have been reported [27]. It would there-
fore be ideal if the concentrations of individual T and
T3 are measured to gain new insight into the physio-
logical roles of these vitamin E isomers in humans
[27]. Evaluation of the metab o l i cr e s p o n s ef o l l o w i n g
T3 supplementation through plasma or serum con-
centration of T3 and a-T is advocated. Our present
study shows that all T3 isomers (a-T3, g-T3, δ-T3)
were detected in plasma and lipoproteins following
supplementation of TRF, although their concentration
was significantly lower compared to that of a-T.
These findings are in agreement with our previous
postprandial observation [19] and several other
human studies that examined the bio-kinetics
[2,13,16,17,20] or physiological effects [9-12,14,15,21]
of T3 supplementation.
Figure 2 Mean (± SEM) a-tocotrienols (a-T3) distributions in triacylglycerol rich particles, TRP (○); LDL (●); and HDL (Δ)o fh e a l t h y
volunteers (n = 10) after supplementation with the tocotrienol-rich fraction (TRF). a-T3 was detected in all lipoprotein fractions starting
from 2 h until 8 h. No a-T3 was detected at 0 h and 24 h (fasted states). Inset: AUC, area under the curve, 0-8 h (arbitrary units) is presented as
mean ± SEM (n = 10) for a-T3 distribution in TRP, LDL and HDL.
Figure 3 Mean (± SEM) g-tocotrienols (g-T3) distributions in triacylglycerol rich particles, TRP (○); LDL (●); and HDL (Δ)o fh e a l t h y
volunteers (n = 10) after supplementation with the tocotrienol-rich fraction. g-T3 was detected in all lipoprotein fractions starting from 2 h
until 8 h. No g-T3 was detected at 0 h and 24 h (fasted states). Inset: AUC, area under the curve, 0-8 h (arbitrary units) is presented as mean ±
SEM (n = 10) for g-T3 distribution in TRP, LDL and HDL.
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following postprandial challenge could assist in elucidat-
ing their preferential absorption into circulating blood.
However, this may not be true for a-T, since the liver
actively secretes a-T into circulating plasma and
impacts final plasma concentration of this vitamin E iso-
mer. a-T was detected in both fasted and postprandial
states in the current study. T3 isomers, including a-T3,
the major T3 isomer in TRF, however was not detected
in the fasted state. Their occurrence throughout the
postprandial state was apparent, only in significantly
lower levels compared to a-T. Despite these observa-
tions, we note that T3 have been demonstrated to have
biological functions well below plasma concentrations
noted in this study (5, 8). Among the T3 isomers, the
absorption rates appear in the order a-T3 > g-T3 > δ-
T3. These findings might explain the possibility of bio-
discrimination between T and T3 isomers in humans.
Such bio-discrimination hasa l s ob e e nd e m o n s t r a t e di n
several animal studies. Ikeda et al. [28] demonstrated
that a-T3 is preferentially absorbed into the lymphatic
circulation compared to g-T3 and δ-T3. Similar observa-
tions were found by Yap et al. [29] who investigated the
influence of route of administration on the absorption
and disposition of a-T3, g-T3 and δ-T3 in rats. Of the 3
isomers, a-T3 achieved the highest concentration and
AUC after an oral ingestion of T3. This was followed by
g-T3 and δ-T3. In humans, plasma concentrations of a-
T3 were 2-fold higher than that of g-T3, and almost 10
times higher than δ-T3 after supplementation with the
same dose of T3 preparations [10]. Similar observations
were also demonstrated in hypercholesterolemic subjects
who received a high g-T3 supplements that contained
≈4-fold concentration of g-T3 than a-T3 [11].
Distribution of T3 isomers in lipoproteins also pro-
vides a better explanation of T3 absorption and trans-
port in circulating plasma. In agreement with our
previous observation [19], T3 were transported in TRP
(chylomicrons + VLDL), LDL and HDL. Several
mechanisms have been postulated to explain this obser-
vations [19] including the selectivity and affinity of
hepatic a-TTP [30], the function of a specific protein
carrier in transporting a-T3 in the intestinal cells [28],
and differences in the methyl groups in the chromanol
rings of T3 [29] that influenced the absorption rate of
each T3 isomers [10]. Following its hepatic uptake, it
would be intriguing to know whether nascent VLDL or
HDL generated from the liver, is readily enriched in T3
from the liver itself. The role of HDL in transporting
vitamin E has recently been identified as one of the pri-
mary mechanisms in vitamin E absorption in the fasted
states [31].
The competitive uptake between isomers is only
initiated following the hepatic uptake of vitamin E from
chylomicrons, where the selectivity role of a-TTP is sig-
nificant in transferring vitamin E into circulating VLDL
[25]. The relative affinity of vitamin E isomers towards
a-TTP has been demonstrated to be in the order of a-T
(100%) > a-T3 (12%) > g-T (9%) > δ-T (2%) [30]. This
mechanism explains the occurrence of a-T as the major
vitamin E isomer detected in TRP, LDL, and HDL, and
the rapid disappearance of a-T3, g-T3 and δ-T3 from
circulating plasma and lipoproteins. Other physiological
factors such as bile, urinary and fecal excretion that may
Figure 4 Mean (± SEM) δ-tocotrienols (δ-T3) distributions in triacylglycerol rich particles, TRP (○); LDL (●)a n dH D L( Δ)o fh e a l t h y
volunteers (n = 10) after supplementation with the tocotrienol-rich fraction. δ-T3 was detected in all lipoprotein fractions starting from 2 h
until 8 h. No δ-T3 was detected at 0 h and 24 h (fasted states). Inset: AUC, area under the curve, 0-8 h (arbitrary units) is presented as mean ±
SEM (n = 10) for δ-T3 distribution in TRP, LDL and HDL.
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Page 8 of 11influence the rapid disappearance of T3 has also been
postulated [19,32]. The exchange of T3 between circu-
lating chylomicron, VLDL, LDL, and HDL has also been
suggested to explain their distribution in the lipopro-
teins [19,20].
There is no bio-discrimination between T and T3 dur-
ing intestinal absorption after dietary intake of vitamin E
[26,33-35]. However, the rapid disappearance of T3 may
be associated with its preferential utilization in humans
(8, 25, 34). In the current and previous [19,20] studies,
the amount of T3 absorbed into TRP was very low. This
observation may indicate the possibility of bio-discrimi-
nation of T3, prior to the intestinal absorption.
Although mechanism for the preferential absorption of
T3 is difficult to describe, it has been suggested that the
complexity of T3 absorption is probably due to the dif-
ference in their micellar solubility, affinity for intestinal
brush border membranes, transport in enterocytes,
incorporation into chylomicrons, or a combination of
these processes [28]. Besides, there might be variability
in the mucosal handling of vitamin E that could affect
their intestinal absorption [36]. Although we did not
separate chylomicrons and VLDL from TRP fraction to
differentiate the T3 uptake from intestine by chylomi-
crons and from liver by VLDL, recent findings from
Abuasal et al. [37] demonstrated that there was an
inverse relationship between intestinal uptake of g-T3
and their concentration in the intestinal lumen. There-
fore, any elevation of g-T3 concentration in the lumen
would likely reduce the amount of g-T3 transported into
the enterocytes. However, no investigations on other T3
isomer were carried out. The intestinal absorption of
T3, as well as T still merits further investigations, since
their mechanism has not been fully described [25]. In
rats, dietary vitamin E including T3 are converted to
their metabolite by CYP-dependent pathway in the
intestine during absorption. This could likely regulate
T3 concentration in plasma and tissue [38]. Yet, excess
intake of T3 has been observed to lead excretion of a-
T3 and g- T 3i n t ob i l e ,b e f o r eb o t hT 3i s o m e r sw e r e
metabolized into a- and g-CEHC derivatives [32].
T h ep o s t p r a n d i a ld o s er e s p o n s ee f f e c to fv i t a m i nEi n
humans has basically been evaluated from the plasma
and lipoproteins profiles of a-T and g-T [39-41]. Sur-
prisingly, no such evidence exists for T3, although T3
always positively imaged as a superior antioxidant com-
pared to T [2,8]. In the previous study [19], we investi-
gated the postprandial response after 1011 mg TRF
supplementation. In fact, this dose used was higher than
the Tolerable Upper Limit Intake (UL) for vitamin E
[22]. One of the rationale of conducting the current
study was to investigate whether supplementation with
526 mg TRF would resulted a similar postprandial
response, in comparison to the dose used in the
previous study [19], since concentrations of vitamin E in
plasma can only be raised maximally two to three-fold
after supplementation [39]. Plasma a-T3, g-T3 and δ-T3
response after TRF treatment in the current study were
not significantly different from the previous study. Addi-
tionally, a-T and g-T concentrations in plasma, TRP,
LDL and HDL were not apparent between both TRF
treatments. However, observations in lipoprotein frac-
tions still remains to be elucidated. In HDL, starting
from 4 h to 6 h postprandial, a-T3 concentration after
526 mg TRF treatment were significantly lower com-
pared to the 1011 mg TRF treatment. These observa-
tions merits further investigation since the
transportation of vitamin E by HDL may possibly be
influenced by supplementation dose and was not
affected by amount of dietary fat intake [31]. In both
postprandial studies, the amount of dietary fat in the
test breakfast consumed before TRF supplementation
was standardized.
Several studies have suggested the effectiveness of T3
as a hypocholesterolemic agent in lowering plasma or
serum total cholesterol in humans [15,42]. Nevertheless,
it is questionable why the effectiveness of T3 in lowering
plasma total cholesterol has not been compared with a-
T, since a-T has been recognized as the only form uti-
lized to estimate human vitamin E requirements.
Furthermore, the effectiveness of T3 in humans was
only compared with a placebo treatment in most studies
[10,15,18,21,42,43]. Although in several studies, physio-
logical effects of T3 was compared with a-T, the con-
centration of a-T in the control preparations or
supplements was very low [9,11,44] Unlike our previous
observation [19] where supplementation with 1011 mg
palm TRF or 1074 mg a-T resulted in significant lower-
ing of plasma postprandial total cholesterol, supplemen-
tation with 526 mg palm TRF or 537 mg a-T in the
current study did not demonstrated any hypocholestero-
lemic effect. Several postulations have been discussed to
explain the inability of T3 to lower plasma or serum
cholesterol in humans such as the higher content of T
in the T3 supplements, in vivo bio-conversion of T3 to
a-T, and very low concentration of T3 that did not
reach the pharmacologically effective level in plasma
[45].
Conclusions
In conclusions, T3 isomers (a-T3, g-T3, and δ-T3) were
present in the circulating plasma and lipoproteins (TRP,
LDL, and HDL) after T3 supplementation. As postu-
lated, T3 concentrations were significantly lower than
a-T. Low absorption into the circulation could affect
the physiological effects of T3, as indicated by their
inability to lower plasma cholesterol in the current post-
prandial study. However, it is somewhat reassuring that
Fairus et al. Nutrition Journal 2012, 11:5
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Page 9 of 11even at the low concentration of circulating T3 in
plasma (approximately 4 nM) T3 could still have benefi-
cial biological functions including that of neuroprotec-
tion as demonstrated by other workers [46].
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